132 related articles for article (PubMed ID: 37173417)
41. Comparable outcome after single-antigen-mismatched versus matched unrelated donor haematopoietic cell transplantation.
Rockstroh A; Al-Ali HK; Lange T; Pönisch W; Krahl R; Cross M; Behre G; Niederwieser D; Pfrepper C
J Cancer Res Clin Oncol; 2015 Dec; 141(12):2193-203. PubMed ID: 26129640
[TBL] [Abstract][Full Text] [Related]
42. Donor Age and Non-Relapse Mortality: Study of Their Association after HLA-Matched Allogeneic Hematopoietic Cell Transplantation for Acute Myeloid Leukemia and Myelodysplastic Syndrome.
Kadri Y; Phan M; Bambace N; Bernard L; Cohen S; Delisle JS; Kiss T; Lachance S; Roy DC; Sauvageau G; Veilleux O; Roy J; Ahmad I
Curr Oncol; 2022 Aug; 29(8):5955-5962. PubMed ID: 36005208
[TBL] [Abstract][Full Text] [Related]
43. Superior survival associated with transplantation of matched unrelated versus one-antigen-mismatched unrelated or highly human leukocyte antigen-disparate haploidentical family donor marrow grafts for the treatment of hematologic malignancies: establishing a treatment algorithm for recipients of alternative donor grafts.
Drobyski WR; Klein J; Flomenberg N; Pietryga D; Vesole DH; Margolis DA; Keever-Taylor CA
Blood; 2002 Feb; 99(3):806-14. PubMed ID: 11806980
[TBL] [Abstract][Full Text] [Related]
44. Comparing outcomes of matched related donor and matched unrelated donor hematopoietic cell transplants in adults with B-Cell acute lymphoblastic leukemia.
Segal E; Martens M; Wang HL; Brazauskas R; Weisdorf D; Sandmaier BM; Khoury HJ; de Lima M; Saber W
Cancer; 2017 Sep; 123(17):3346-3355. PubMed ID: 28452054
[TBL] [Abstract][Full Text] [Related]
45. CD6+ T cell depleted allogeneic bone marrow transplantation from genotypically HLA nonidentical related donors.
Soiffer RJ; Mauch P; Fairclough D; Alyea E; Anderson K; Fisher D; Freedman A; Bartlett-Pandite L; Robertson M; Schlossman R; Gollob J; Marcus K; Murray C; Kuhlman C; Freeman A; Nadler L; Ritz J
Biol Blood Marrow Transplant; 1997 Apr; 3(1):11-7. PubMed ID: 9209736
[TBL] [Abstract][Full Text] [Related]
46. Predictive Factors and Outcomes after Allogeneic Stem Cell Transplantation for Adults with Acute Lymphoblastic Leukemia in Brazil.
Silva WF; Cysne DN; Kerbauy MN; Colturato I; Maia ACA; Tucunduva L; Barros GMN; Colturato VAR; Hamerschlak N; Rocha V
Transplant Cell Ther; 2022 Nov; 28(11):763.e1-763.e7. PubMed ID: 35914726
[TBL] [Abstract][Full Text] [Related]
47. Clinical implications of HLA locus mismatching in unrelated donor hematopoietic cell transplantation: a meta-analysis.
Tie R; Zhang T; Yang B; Fu H; Han B; Yu J; Tan Y; Huang H
Oncotarget; 2017 Apr; 8(16):27645-27660. PubMed ID: 28206973
[TBL] [Abstract][Full Text] [Related]
48. Post-transplantation cyclophosphamide GvHD prophylaxis after hematopoietic stem cell transplantation from 9/10 or 10/10 HLA-matched unrelated donors for acute leukemia.
Lorentino F; Labopin M; Ciceri F; Vago L; Fleischhauer K; Afanasyev B; Kröger N; Cornelissen JJ; Lovira M; Meijer E; Vitek A; Elmaagacli A; Blaise D; Ruggeri A; Chabannon C; Nagler A; Mohty M;
Leukemia; 2021 Feb; 35(2):585-594. PubMed ID: 32409688
[TBL] [Abstract][Full Text] [Related]
49. Poor outcome with nonmyeloablative conditioning regimen before cord blood transplantation for patients with high-risk acute myeloid leukemia compared with matched related or unrelated donor transplantation.
Devillier R; Harbi S; Fürst S; Crocchiolo R; El-Cheikh J; Castagna L; Etienne A; Calmels B; Lemarie C; Prebet T; Granata A; Charbonnier A; Rey J; Chabannon C; Faucher C; Vey N; Blaise D
Biol Blood Marrow Transplant; 2014 Oct; 20(10):1560-5. PubMed ID: 24933658
[TBL] [Abstract][Full Text] [Related]
50. Outcomes after transplantation of cord blood or bone marrow from unrelated donors in adults with leukemia.
Laughlin MJ; Eapen M; Rubinstein P; Wagner JE; Zhang MJ; Champlin RE; Stevens C; Barker JN; Gale RP; Lazarus HM; Marks DI; van Rood JJ; Scaradavou A; Horowitz MM
N Engl J Med; 2004 Nov; 351(22):2265-75. PubMed ID: 15564543
[TBL] [Abstract][Full Text] [Related]
51. Unrelated donor versus matched sibling donor in adults with acute myeloid leukemia in first relapse: an ALWP-EBMT study.
Ruggeri A; Battipaglia G; Labopin M; Ehninger G; Beelen D; Tischer J; Ganser A; Schwerdtfeger R; Glass B; Finke J; Michallet M; Stelljes M; Jindra P; Arnold R; Kröger N; Mohty M; Nagler A
J Hematol Oncol; 2016 Sep; 9(1):89. PubMed ID: 27639553
[TBL] [Abstract][Full Text] [Related]
52. Human leukocyte antigen supertype matching after myeloablative hematopoietic cell transplantation with 7/8 matched unrelated donor allografts: a report from the Center for International Blood and Marrow Transplant Research.
Lazaryan A; Wang T; Spellman SR; Wang HL; Pidala J; Nishihori T; Askar M; Olsson R; Oudshoorn M; Abdel-Azim H; Yong A; Gandhi M; Dandoy C; Savani B; Hale G; Page K; Bitan M; Reshef R; Drobyski W; Marsh SG; Schultz K; Müller CR; Fernandez-Viña MA; Verneris MR; Horowitz MM; Arora M; Weisdorf DJ; Lee SJ
Haematologica; 2016 Oct; 101(10):1267-1274. PubMed ID: 27247320
[TBL] [Abstract][Full Text] [Related]
53. Comparable outcomes of partially matched related and matched related allogeneic hematopoietic cell transplantation following reduced-intensity conditioning in adult patients with Philadelphia chromosome-negative acute lymphoblastic leukemia.
Wu X; He G; Fa Y; Ma X; Wu D; Ai H; Huang X; Han Y; Xu Y; Sun A; Wu Q; Tang X; Fu Z
Int J Hematol; 2013 Oct; 98(4):456-62. PubMed ID: 23975518
[TBL] [Abstract][Full Text] [Related]
54. PTCY and Tacrolimus for GVHD Prevention for Older Adults Undergoing HLA-Matched Sibling and Unrelated Donor AlloHCT.
Salas MQ; Charry P; Pedraza A; Martínez-Cibrian N; Solano MT; Domènech A; Suárez-Lledó M; Nomdedeu M; Cid J; Lozano M; de-LLobet N; Arcarons J; Rosiñol L; Gutiérrez-García G; Carreras E; Esteve J; Urbano-Ispizua Á; Fernández-Avilés F; Rovira M; Martínez C
Transplant Cell Ther; 2022 Aug; 28(8):489.e1-489.e9. PubMed ID: 35577323
[TBL] [Abstract][Full Text] [Related]
55. Posttransplantation Cyclophosphamide- and Sirolimus-Based Graft-Versus-Host-Disease Prophylaxis in Allogeneic Stem Cell Transplant.
Greco R; Lorentino F; Albanese S; Lupo Stanghellini MT; Giglio F; Piemontese S; Clerici D; Lazzari L; Marcatti M; Mastaglio S; Xue E; Farina F; Pavesi F; Assanelli A; Carrabba MG; Marktel S; Vago L; Bonini C; Corti C; Bernardi M; Ciceri F; Peccatori J
Transplant Cell Ther; 2021 Sep; 27(9):776.e1-776.e13. PubMed ID: 34087452
[TBL] [Abstract][Full Text] [Related]
56. Different effects of thymoglobulin on acute leukemia with pre-transplant residual blasts in HLA mismatch transplantation.
Wakamatsu M; Murata M; Kanda J; Fukushima K; Fukuda T; Najima Y; Katayama Y; Ozawa Y; Tanaka M; Kanda Y; Eto T; Takada S; Kako S; Uchida N; Kawakita T; Yoshiko H; Ichinohe T; Atsuta Y; Terakura S;
Int J Hematol; 2023 Jun; 117(6):889-899. PubMed ID: 36814041
[TBL] [Abstract][Full Text] [Related]
57. Donor Type and Disease Risk Predict the Success of Allogeneic Hematopoietic Cell Transplantation: A Single-Center Analysis of 613 Adult Hematopoietic Cell Transplantation Recipients Using a Modified Composite Endpoint.
Solh M; Zhang X; Connor K; Brown S; Morris LE; Holland HK; Bashey A; Solomon SR
Biol Blood Marrow Transplant; 2017 Dec; 23(12):2192-2198. PubMed ID: 28864140
[TBL] [Abstract][Full Text] [Related]
58. Allogeneic bone marrow transplantation from unrelated human T-cell leukemia virus-I-negative donors for adult T-cell leukemia/lymphoma: retrospective analysis of data from the Japan Marrow Donor Program.
Kato K; Kanda Y; Eto T; Muta T; Gondo H; Taniguchi S; Shibuya T; Utsunomiya A; Kawase T; Kato S; Morishima Y; Kodera Y; Harada M;
Biol Blood Marrow Transplant; 2007 Jan; 13(1):90-9. PubMed ID: 17222757
[TBL] [Abstract][Full Text] [Related]
59. Reduced-intensity allogeneic transplant in patients older than 55 years: unrelated umbilical cord blood is safe and effective for patients without a matched related donor.
Majhail NS; Brunstein CG; Tomblyn M; Thomas AJ; Miller JS; Arora M; Kaufman DS; Burns LJ; Slungaard A; McGlave PB; Wagner JE; Weisdorf DJ
Biol Blood Marrow Transplant; 2008 Mar; 14(3):282-9. PubMed ID: 18275894
[TBL] [Abstract][Full Text] [Related]
60. Results of a 2-arm, phase 2 clinical trial using post-transplantation cyclophosphamide for the prevention of graft-versus-host disease in haploidentical donor and mismatched unrelated donor hematopoietic stem cell transplantation.
Gaballa S; Ge I; El Fakih R; Brammer JE; Kongtim P; Tomuleasa C; Wang SA; Lee D; Petropoulos D; Cao K; Rondon G; Chen J; Hammerstrom A; Lombardi L; Alatrash G; Korbling M; Oran B; Kebriaei P; Ahmed S; Shah N; Rezvani K; Marin D; Bashir Q; Alousi A; Nieto Y; Qazilbash M; Hosing C; Popat U; Shpall EJ; Khouri I; Champlin RE; Ciurea SO
Cancer; 2016 Nov; 122(21):3316-3326. PubMed ID: 27404668
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]